Cancer Communications

Papers
(The TQCC of Cancer Communications is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020350
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy314
Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020313
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021278
Cancer burden of major cancers in China: A need for sustainable actions249
LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer238
A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysis174
Emerging role of deep learning‐based artificial intelligence in tumor pathology158
Ferroptosis in cancer and cancer immunotherapy156
EMT‐associated microRNAs and their roles in cancer stemness and drug resistance138
Boron neutron capture therapy: Current status and future perspectives127
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma113
Non‐small cell lung cancer in China112
CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target108
Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy101
The FTO/miR‐181b‐3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer98
Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review95
The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer91
Global and regional burdens of oral cancer from 1990 to 2017: Results from the global burden of disease study88
Advancing to the era of cancer immunotherapy84
A global assessment of recent trends in gastrointestinal cancer and lifestyle‐associated risk factors76
New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer69
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase 69
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy68
Aberrant translation regulated by METTL1/WDR4‐mediated tRNA N7‐methylguanosine modification drives head and neck squamous cell carcinoma progression68
Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art65
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma64
Breast cancer: an up‐to‐date review and future perspectives63
Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine61
Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma58
The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential55
New insights into molecules and pathways of cancer metabolism and therapeutic implications52
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities49
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy44
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy43
Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells43
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program41
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges40
Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China40
Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa‐miR‐6887‐3p39
Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma39
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA39
The theory of tumor ecosystem37
Trends in cancer mortality in China from 2004 to 2018: A nationwide longitudinal study37
S100A8 promotes epithelial‐mesenchymal transition and metastasis under TGF‐β/USF2 axis in colorectal cancer36
The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells36
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine35
Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy34
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives34
Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 133
Correlation between the genetic variants of base excision repair (BER) pathway genes and neuroblastoma susceptibility in eastern Chinese children31
Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma29
Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer29
Squalene epoxidase promotes colorectal cancer cell proliferation through accumulating calcitriol and activating CYP24A1‐mediated MAPK signaling29
The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990–201729
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors28
Programmed death ligand‐1 regulates angiogenesis and metastasis by participating in the c‐JUN/VEGFR2 signaling axis in ovarian cancer28
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates28
Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis27
Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors27
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer26
The EGFR‐P38 MAPK axis up‐regulates PD‐L1 through miR‐675‐5p and down‐regulates HLA‐ABC via hexokinase‐2 in hepatocellular carcinoma cells26
Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma26
An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment26
Application of erector spinae plane block guided by ultrasound for postoperative analgesia in breast cancer surgery: A randomized controlled trial25
A newly discovered role of metabolic enzyme PCK1 as a protein kinase to promote cancer lipogenesis25
Analysis of the Global Burden of Disease study highlights the trends in death and disability‐adjusted life years of leukemia from 1990 to 201724
N6‐methyladenosine Steers RNA Metabolism and Regulation in Cancer23
Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer23
Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T‐cell acute lymphoblastic leukemia23
T‐cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: A methodology and clinical applications23
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities23
Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor22
Predictions of mortality related to four major cancers in China, 2020 to 203022
Elevated neutrophil extracellular traps by HBV‐mediated S100A9‐TLR4/RAGE‐ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma22
Activation of Piezo1 contributes to matrix stiffness‐induced angiogenesis in hepatocellular carcinoma21
KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression21
Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox20
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, r20
Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis20
PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism20
Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?20
CRISPR/Cas9 screening identifies a kinetochore‐microtubule dependent mechanism for Aurora‐A inhibitor resistance in breast cancer20
Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis19
Metabolic regulation in the immune response to cancer19
Tumor microenvironment signaling and therapeutics in cancer progression19
Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β2‐AR/MACC1 axis18
Gene amplification‐driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A‐YTHDF2‐dependent in lung adenocarcinoma18
Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?18
Haploidentical‐ versus identical‐sibling transplant for high‐risk pediatric AML: A multi‐center study18
Exhaled breath diagnostics of lung and gastric cancers in China using nanosensors18
Emerging radiotherapy technologies and trends in nasopharyngeal cancer17
RGS12 inhibits the progression and metastasis of multiple myeloma by driving M1 macrophage polarization and activation in the bone marrow microenvironment17
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib17
Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma16
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions16
Ki‐67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study16
Expert opinions on immunotherapy for patients with colorectal cancer16
ZNF582 hypermethylation promotes metastasis of nasopharyngeal carcinoma by regulating the transcription of adhesion molecules Nectin‐3 and NRXN316
Lipid metabolism in pancreatic cancer: emerging roles and potential targets16
YB1 regulates miR‐205/200b‐ZEB1 axis by inhibiting microRNA maturation in hepatocellular carcinoma16
Phosphatidylserine released from apoptotic cells in tumor induces M2‐like macrophage polarization through the PSR‐STAT3‐JMJD3 axis16
The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation16
LncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex‐mediated changes in chromatin structure in lung adenocarcinoma15
Spatial metabolomics for evaluating response to neoadjuvant therapy in non‐small cell lung cancer patients15
Harness the functions of gut microbiome in tumorigenesis for cancer treatment15
Infection complications in febrile chimeric antigen receptor (CAR)‐T recipients during the peri‐CAR‐T cell treatment period examined using metagenomic next‐generation sequencing (mNGS)15
Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges15
Ovarian cancer‐excreted exosomal miR‐199a‐5p suppresses tumor metastasis by targeting hypoxia‐inducible factor‐2α in hypoxia microenvironment15
The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large‐scale cohort study in China14
Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China14
Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients14
Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 414
Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives14
METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression14
Mitochondrial transcription factor A plays opposite roles in the initiation and progression of colitis‐associated cancer14
Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden14
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study13
P300/CBP‐associated factor (PCAF)‐mediated acetylation of Fascin at lysine 471 inhibits its actin‐bundling activity and tumor metastasis in esophageal cancer13
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A m13
BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma13
m6A‐mediated regulation of PBX1‐GCH1 axis promotes gastric cancer proliferation and metastasis by elevating tetrahydrobiopterin levels13
Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China13
Antibody variable region engineering for improving cancer immunotherapy12
CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma12
Abscopal effect of stereotactic radiotherapy combined with anti‐PD‐1/PD‐L1 immunotherapy: Mechanisms, clinical efficacy, and issues12
Dicer‐independent snRNA/snoRNA‐derived nuclear RNA 3 regulates tumor‐associated macrophage function by epigenetically repressing inducible nitric oxide synthase transcription12
Snail acetylation by autophagy‐derived acetyl‐coenzyme A promotes invasion and metastasis of KRASLKB1 co‐mutated lung cancer cells12
The role of myeloid‐derived suppressor cells in gastrointestinal cancer12
Crosstalk between IL‐15Rα+tumor‐associated macrophages and breast cancer cells reduces CD8+T cell recruitment12
Macrophage inhibitory cytokine‐1 induced by a high‐fat diet promotes prostate cancer progression by stimulating tumor‐promoting cytokine production from tumor stromal cells11
miR‐495 and miR‐5688 are down‐regulated in non‐small cell lung cancer under hypoxia to maintain interleukin‐11 expression11
Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials11
Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management11
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation11
A novel intronic circular RNA, circGNG7, inhibits head and neck squamous cell carcinoma progression by blocking the phosphorylation of heat shock protein 27 at Ser78 and Ser8211
A new mouse esophageal cancer cell line (mEC25)‐derived pre‐clinical syngeneic tumor model for immunotherapy11
Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma11
A non‐metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11‐mediated CD133 stability11
0.042325973510742